BNR

Burning Rock Biotech

29.14 USD
-1.13
3.73%
At close Updated Feb 13, 4:00 PM EST
Pre-market
After hours
29.00
-0.14
0.48%
1 day
-3.73%
5 days
-14.94%
1 month
21.06%
3 months
157.42%
6 months
316.88%
Year to date
48.07%
1 year
374.59%
5 years
-91.29%
10 years
-88.17%
 

About: Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Employees: 674

0
Funds holding %
of 7,560 funds
Analysts bullish %
Positive news %
Price charts implemented using Lightweight Charts™